Cargando…

Computational Investigations on the Natural Small Molecule as an Inhibitor of Programmed Death Ligand 1 for Cancer Immunotherapy

Several therapeutic monoclonal antibodies approved by the FDA are available against the PD-1/PD-L1 (programmed death 1/programmed death ligand 1) immune checkpoint axis, which has been an unprecedented success in cancer treatment. However, existing therapeutics against PD-L1, including small molecul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, Geethu S, Moustafa, Mahmoud, Sahoo, Amaresh Kumar, Malý, Petr, Bharadwaj, Shiv
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145275/ https://www.ncbi.nlm.nih.gov/pubmed/35629327 http://dx.doi.org/10.3390/life12050659

Ejemplares similares

Editorial: Advances in the therapeutic targeting of human matrix metalloproteinases in health and disease
por: Bharadwaj, Shiv, et al.
Publicado: (2023)

Drug repurposing for ligand-induced rearrangement of Sirt2 active site-based inhibitors via molecular modeling and quantum mechanics calculations
por: Bharadwaj, Shiv, et al.
Publicado: (2021)

Determination of tyrosinase-cyanidin-3-O-glucoside and (−/+)-catechin binding modes reveal mechanistic differences in tyrosinase inhibition
por: Lee, Kyung Eun, et al.
Publicado: (2021)

Targeting programmed death ligand 2/repulsive guidance molecule b pathway: a novel strategy to subdue tumor immunotherapy resistance to anti‐programmed death 1/programmed death ligand 1
por: Xiang, Yuancai, et al.
Publicado: (2023)

Understanding on the possible routes for SARS CoV-2 invasion via ACE2 in the host linked with multiple organs damage
por: Kirtipal, Nikhil, et al.
Publicado: (2022)

Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy
por: Gutic, Bojana, et al.
Publicado: (2023)

Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy
por: Jiang, Yao, et al.
Publicado: (2023)

Structure-Based Identification of Natural Products as SARS-CoV-2 M(pro) Antagonist from Echinacea angustifolia Using Computational Approaches
por: Bharadwaj, Shiv, et al.
Publicado: (2021)

Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1
por: Zhao, Jing, et al.
Publicado: (2020)

Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer
por: Núñez Abad, Martín, et al.
Publicado: (2022)

Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction
por: Muszak, Damian, et al.
Publicado: (2021)

Corrigendum: Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1
Publicado: (2021)

Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors
por: Kareff, Samuel A., et al.
Publicado: (2021)

Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1
por: Park, Jang-June, et al.
Publicado: (2021)

Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy
por: Wang, Aoyun, et al.
Publicado: (2021)

Identification of key genes of anti-programmed death ligand 1 for meningioma immunotherapy by bioinformatic analysis
por: Zhang, Lijian, et al.
Publicado: (2022)

In Silico Study of a Small Bioactive Molecule Targeting Topoisomerase II and P53-MDM2 Complex in Triple-Negative Breast Cancer
por: Singh, Vishal, et al.
Publicado: (2023)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
por: Zak, Krzysztof M., et al.
Publicado: (2016)

Immune checkpoint molecules soluble program death ligand 1 and galectin‐9 are increased in pregnancy
por: Enninga, Elizabeth Ann L., et al.
Publicado: (2017)

Effects of small molecule-induced dimerization on the programmed death ligand 1 protein life cycle
por: Chai, Ilean, et al.
Publicado: (2022)

Design and Biological Evaluation of Small-Molecule PET-Tracers for Imaging of Programmed Death Ligand 1
por: Krutzek, Fabian, et al.
Publicado: (2023)

Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells
por: Kamata, Toshiko, et al.
Publicado: (2016)

Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction
por: Shaabani, Shabnam, et al.
Publicado: (2022)

Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells
por: Sukowati, Caecilia H C, et al.
Publicado: (2021)

In silico approach for identifying natural lead molecules against SARS-COV-2
por: Gupta, Shiv Shankar, et al.
Publicado: (2021)

CD95 ligand - death factor and costimulatory molecule?
por: Janssen, O, et al.
Publicado: (2003)

Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer
por: Yang, Hanshen, et al.
Publicado: (2022)

Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics
por: Abaza, Abdelrahman, et al.
Publicado: (2023)

Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma
por: HAN, LIJUAN, et al.
Publicado: (2014)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2021)

Microsatellite Instability, Epstein–Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer
por: Yu, Hung-Yuan, et al.
Publicado: (2022)

Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer
por: Li, Xintong, et al.
Publicado: (2022)

Efficacy and safety of programmed cell death-1/programmed cell death ligand-1 inhibitors in advanced urothelial malignancy: A systematic review and meta-analysis
por: Pattanaik, Smita, et al.
Publicado: (2019)

IL-1β, But Not Programed Death-1 and Programed Death Ligand Pathway, Is Critical for the Human Th17 Response to Mycobacterium tuberculosis
por: Stephen-Victor, Emmanuel, et al.
Publicado: (2016)

Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy
por: Qi, Yihang, et al.
Publicado: (2021)

Bioengineering and computational analysis of programmed cell death ligand-1 monoclonal antibody
por: Kalim, Muhammad, et al.
Publicado: (2022)

Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis
por: Deepak, H. B., et al.
Publicado: (2022)

Pseudopyronine B: A Potent Antimicrobial and Anticancer Molecule Isolated from a Pseudomonas mosselii
por: Nishanth Kumar, S., et al.
Publicado: (2016)

Computational and In Vitro Investigation of (-)-Epicatechin and Proanthocyanidin B2 as Inhibitors of Human Matrix Metalloproteinase 1
por: Lee, Kyung Eun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cf0bss3trqk7lrar8n5fj7d4bk